China’s drug regulator has given conditional approval for the mass use of two additional COVID-19 vaccines produced by Chinese pharmaceutical firms, bringing the total number of home-produced vaccines granted conditional approval for mass use to four.
Vaccines developed by Sinopharm’s research institute in Wuhan, Central China’s Hubei Province, and another produced by CanSino have been granted conditional approval for mass use, according to a statement posted on the website of China’s National Medical Products Administration on Thursday.
The approvals were granted under an emergency protocol and the two companies will continue to conduct research, meet the conditions required by the administration and submit research results in a timely manner.
Tao Lina, a Shanghai-based expert on vaccines and a former employee at the Shanghai Disease Prevention and Control, told the Global Times that the authorization on Thursday makes China so far the world’s only country to have COVID-19 vaccines approved for mass use from two technological routes, adding a new option to the efforts to control the pandemic.
Tao noted that more options mean more flexibility in the assessment work, something other countries don’t enjoy at the moment.
Pakistan officials mentioned in early February that CanSino’s COVID-19 recombinant adenovirus vector vaccine showed 90.98 percent efficacy rate in preventing severe disease in interim analysis and is effective to prevent 65.7 percent of symptomatic diseases in clinical trials conducted in Pakistan and other countries.
Sinopharm’s research institute in Wuhan said this week that their inactivated COVID-19 vaccine shows an efficacy of 72.51 percent after two shots in phase III clinical trials.
Previously, two homegrown vaccines have already been granted approval by the health authorities.
An inactivated vaccine developed by Beijing Biological Products Institute under Sinopharm’s subsidiary, China National Biotec Group (CNBG), was China’s first COVID-19 vaccine to receive conditional approval for the country’s domestic market on December 31, 2020. It was followed by CoronaVac, developed by Chinese pharmaceutical firm Sinovac Biotech.
Source: Global Times
more recommended stories
Online shopping festival held to promote integration of Greater Bay Area
The first online shopping festival of.
Livestream marketing, upgraded logistics drive sales of bananas in S China’s Nanning
Livestream marketing and logistics reform, as.
“Share The Moment” Short Video Contest Announcement
The moment started from 50 years.
Population of green peafowl sees steady recovery in China
In recent years, China has significantly.
Small home appliance market flourishes in China
China’s small home appliance market witnessed.
Chinese cities actively adapt home environment for safety, comfort of the elderly
Chinese cities are trying to ensure.
China’s 14th National Games kicks off in Xi’an
China’s 14th National Games began in.
China goes full steam ahead to push international anti-pandemic cooperation
As the COVID-19 pandemic is still.
Unmanned agricultural machinery widely used in China
Intelligent agricultural machinery is now easily.
China’s manufacturing value-added ranks first in the world for 11 years
China has maintained its position as.